A recent systematic review of 49 studies showed that RA patients who used a TNF-inhibitor did not have an additional increased risk for malignancies in general, nor for lymphoma or non-melanoma skin cancer as compared to RA patients who did not use a TNF-inhibitor. Here, TNF is linked to lymphoma.